Examination of the Novel Sigma-1 Receptor Antagonist, SI 1/28, for Antinociceptive and Anti-allodynic Efficacy against Multiple Types of Nociception with Fewer Liabilities of Use

Neuropathic pain is a significant problem with few effective treatments lacking adverse effects. The sigma-1 receptor (S1R) is a potential therapeutic target for neuropathic pain, as antagonists for this receptor effectively ameliorate pain in both preclinical and clinical studies. The current resea...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Lisa L., Eans, Shainnel O., Ramadan-Siraj, Insitar, Modica, Maria N., Romeo, Giuseppe, Intagliata, Sebastiano, McLaughlin, Jay P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8775934/
https://www.ncbi.nlm.nih.gov/pubmed/35054797
http://dx.doi.org/10.3390/ijms23020615

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8775934/
https://www.ncbi.nlm.nih.gov/pubmed/35054797
http://dx.doi.org/10.3390/ijms23020615

Ejemplares similares